Compare Stocks: ALPN, JAZZ, NBIX, and ELAN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	N/A
ELAN Elanco Animal Health	$22.26 +0.6%	$24.67	$16.89 ▼ $27.98	$11.05B	1.67	6.93 million shs	22.47 million shs
JAZZ Jazz Pharmaceuticals	$256.52 0.0%	$241.76	$110.26 ▼ $265.05	$16.65B	0.32	786,218 shs	896,535 shs
NBIX Neurocrine Biosciences	$164.92 +0.9%	$168.57	$122.14 ▼ $186.12	$16.61B	0.39	1.38 million shs	935,225 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
ELAN Elanco Animal Health	0.00%	-16.52%	-11.19%	+1.79%	+32.80%
JAZZ Jazz Pharmaceuticals	0.00%	+1.46%	+5.23%	+14.74%	+130.51%
NBIX Neurocrine Biosciences	0.00%	-2.03%	-7.74%	+8.51%	+30.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	N/A
ELAN Elanco Animal Health	$22.26 +0.6%	$24.67	$16.89 ▼ $27.98	$11.05B	1.67	6.93 million shs	22.47 million shs
JAZZ Jazz Pharmaceuticals	$256.52 0.0%	$241.76	$110.26 ▼ $265.05	$16.65B	0.32	786,218 shs	896,535 shs
NBIX Neurocrine Biosciences	$164.92 +0.9%	$168.57	$122.14 ▼ $186.12	$16.61B	0.39	1.38 million shs	935,225 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
ELAN Elanco Animal Health	0.00%	-16.52%	-11.19%	+1.79%	+32.80%
JAZZ Jazz Pharmaceuticals	0.00%	+1.46%	+5.23%	+14.74%	+130.51%
NBIX Neurocrine Biosciences	0.00%	-2.03%	-7.74%	+8.51%	+30.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	0.00	N/A	N/A	N/A
ELAN Elanco Animal Health	2.77	Moderate Buy	$29.09	30.69% Upside
JAZZ Jazz Pharmaceuticals	2.95	Moderate Buy	$272.74	6.32% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$201.50	22.18% Upside

Current Analyst Ratings Breakdown

Latest ALPN, JAZZ, NBIX, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	ELAN Elanco Animal Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $33.00
8/6/2026	ELAN Elanco Animal Health	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$29.00 ➝ $30.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Buy (B-)
8/4/2026	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$287.00
8/4/2026	JAZZ Jazz Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$275.00 ➝ $300.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$254.00 ➝ $264.00
8/4/2026	JAZZ Jazz Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$315.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$285.00 ➝ $300.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$275.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$301.00 ➝ $310.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$260.00 ➝ $270.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
ELAN Elanco Animal Health	$4.72B	2.36	$2.34 per share	9.53	$13.18 per share	1.69
JAZZ Jazz Pharmaceuticals	$4.60B	3.62	$16.26 per share	15.78	$71.07 per share	3.61
NBIX Neurocrine Biosciences	$3.37B	4.97	$5.06 per share	32.60	$32.63 per share	5.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	17.81	1.32	-3.96%	8.13%	3.99%	N/A
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	17.69	11.52	0.23	20.45%	33.97%	13.02%	N/A
NBIX Neurocrine Biosciences	$478.60M	$6.82	24.18	16.95	0.58	20.91%	22.43%	15.64%	10/27/2026 (Estimated)

Latest ALPN, JAZZ, NBIX, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	9.56	9.56
ELAN Elanco Animal Health	0.58	2.05	1.10
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
ELAN Elanco Animal Health	97.48%
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
ELAN Elanco Animal Health	1.14%
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	No Data
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable

ALPN, JAZZ, NBIX, and ELAN Headlines

Recent News About These Companies

Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX

August 10 at 3:20 AM | marketbeat.com

Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

August 9 at 3:27 AM | marketbeat.com

Neurocrine Biosciences (NASDAQ:NBIX) Lowered to Hold Rating by Wall Street Zen

August 9 at 1:12 AM | americanbankingnews.com

Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by Wall Street Zen

August 9 at 1:11 AM | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers

August 8 at 3:28 AM | marketbeat.com

Neurocrine Biosciences Begins Phase 1 Trial of Obesity Drug Candidate

August 7 at 7:16 PM | finance.yahoo.com

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7 at 7:12 PM | seekingalpha.com

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

August 7 at 8:30 AM | prnewswire.com

Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC

August 7 at 6:31 AM | marketbeat.com

Zacks Research Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Hold

August 6, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX

August 5, 2026 | marketbeat.com

Quantinno Capital Management LP Buys 42,508 Shares of Neurocrine Biosciences, Inc. $NBIX

August 5, 2026 | marketbeat.com

BDF Gestion Invests $2 Million in Neurocrine Biosciences, Inc. $NBIX

August 5, 2026 | marketbeat.com

Wedbush Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock

August 5, 2026 | americanbankingnews.com

Truist Financial Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $213.00

August 5, 2026 | americanbankingnews.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock

August 5, 2026 | americanbankingnews.com

Private Client Services LLC Trims Stake in Neurocrine Biosciences, Inc. $NBIX

August 4, 2026 | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Pacer Advisors Inc.

August 4, 2026 | marketbeat.com

Amundi Raises Position in Neurocrine Biosciences, Inc. $NBIX

August 4, 2026 | marketbeat.com

Canaccord Genuity Group Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

August 3, 2026 | marketbeat.com

Truist Financial Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $213.00

August 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, JAZZ, NBIX, and ELAN Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Elanco Animal Health NYSE:ELAN

$22.26 +0.14 (+0.63%)

As of 03:58 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Jazz Pharmaceuticals NASDAQ:JAZZ

$256.52 -0.04 (-0.02%)

As of 04:00 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$164.92 +1.51 (+0.92%)

As of 04:00 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPN, JAZZ, NBIX, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPN, JAZZ, NBIX, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPN, JAZZ, NBIX, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, JAZZ, NBIX, and ELAN Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Elanco Animal Health NYSE:ELAN

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPN, JAZZ, NBIX, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPN, JAZZ, NBIX, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPN, JAZZ, NBIX, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, JAZZ, NBIX, and ELAN Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Elanco Animal Health NYSE:ELAN

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools